Immune Checkpoint Inhibitor in Hepatocellular Carcinoma: Response Rates, Adverse Events, and Predictors of Response

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(3), P. 1034 - 1034

Published: Feb. 6, 2025

Background/Objectives: Hepatocellular carcinoma (HCC) is the most common primary hepatic malignancy. Barcelona Clinic Liver Cancer (BCLC) guidelines recommend antiangiogenic agents with immune checkpoint inhibitors as first-line therapy for advanced HCC. We present our experience of treating HCC patients Atezolizumab-Bevacizumab, their response rates, adverse events, survival, and survival predictors. Methods: This retrospective analysis included diagnosed at All India Institute Medical Sciences, New Delhi, between July 2021 April 2024 receiving least one dose Atezolizumab-Bevacizumab. The outcome was overall rate (ORR), comprising complete (CR) partial (PR), per mRECIST criteria. Secondary outcomes were (OS), progression-free (PFS), predictors survival. Results: Sixty-three analyzed {mean age: 56.0 + 12.7 years; 82.5% males}. Forty-three (68.2%) had BCLC stage C Thirty-five (55.5%) belonged to Child-Pugh class A 28 (44.5%) B. At 1 year, OS 39% PFS 27%. Among 43 data radiological response, ORR 48.8% (CR-9.3% PR-39.5%) DCR 62.7% stable disease (SD) in 13.9% patients. PD occurred 37.2% AFP predicted while Adverse events reported 49.2% Conclusions: Our study shows slightly lower than previous studies being important determinant predicts not

Language: Английский

Serum albumin level is associated with mortality and hospital stays: a real-world data analysis

Clinical Nutrition ESPEN, Journal Year: 2024, Volume and Issue: 64, P. 215 - 220

Published: Oct. 11, 2024

Language: Английский